Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
VNRXShowing New Indication for Nu.Q® NETs HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference...
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
VNRXHENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be...
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
VNRXHENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to...
Volition Sponsors Symposium at Veterinary Meeting and Expo
VNRXHENDERSON, Nev., Jan. 16, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an industry symposium at the world's leading veterinary education conference, Veterinary Meeting and Expo ("VMX") in...
VolitionRx Secures $2.0 Million in Funding
VNRXHENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement (the "Amended Agreement") with Lind...
Volition Issues Business Review 2025
VNRXHENDERSON, Nev., Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025. Review of the Year by Cameron Reynolds, Group Chief Executive Officer As 2025 draws to a close, I would like to...
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
VNRXConference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Nov. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 14 at 8.30 a.m. U.S. Eastern...
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
VNRXConference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial...
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
VNRXConference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to...
VolitionRx Announces Publication Of New Clinical Manuscript Suggesting That Nu.Q H3.1 Biomarker Has Potential To Inform Clinical Care In Critically-Ill ICU Patients In Assessment Of Sepsis, Organ Failure And Subphenotypes
VNRXJones Trading Initiates Coverage On VolitionRX with Buy Rating, Announces Price Target of $3
VNRXReported Earlier, Volition To Present Nu.Q Vet Cancer Test Findings At AMAMS 2025, Highlighting Diagnostic Utility In Canine Oncology
VNRXVolitionRx Publishes Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats In BMC Veterinary Research
VNRXVolitionRX Q1 EPS $(0.06) Up From $(0.10) YoY, Sales $246.38K Up From $171.53K YoY
VNRXVolitionRX Earnings Preview
VNRXD. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
VNRXHC Wainwright & Co. Reiterates Buy on VolitionRX, Maintains $2.5 Price Target
VNRXHC Wainwright & Co. Initiates Coverage On VolitionRX with Buy Rating, Announces Price Target of $2.5
VNRXD. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
VNRXVolitionRX FY Sales $1.200M Miss $1.796M Estimate
VNRXA Look Ahead: VolitionRX's Earnings Forecast
VNRXVolitionRx Announces Pricing Of Up To $2.3M Registered Direct Offering Up Front At $0.55 Per Share With Up To An Additional $1.1M Of Potential Aggerate Gross Proceeds
VNRXVolitionRX Announces Automated Nu.Q Cancer Test Detects 21 Cancer Types at High Specificity with Low False Positive Rate Among Healthy Patients; Potential for Use as Standalone Pan-Cancer Test or in Conjunction with Other Biopsy Technologies
VNRXD. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
VNRXVolition Signs Nu.Q Vet Cancer Test Automation Agreement With Fujifilm Vet Systems
VNRXD. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
VNRXVolitionRX Announces First Patient Enrollment In A Clinical Study Evaluating The Company's Proprietary Nu.Q Cancer Technology For Distinguishing Between Malignant And Benign Pulmonary Nodules
VNRXD. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
VNRXD. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
VNRXVolitionRX Q3 2024 GAAP EPS $(0.07), Inline, Sales $474.522K Miss $652.000K Estimate
VNRXVolitionRx Appoints Timothy I. Still As Chairman Of Its Board Of Directors, Effective November 06, 2024
VNRXEF Hutton Maintains Buy on VolitionRX, Maintains $5 Price Target
VNRXCantor Fitzgerald Reiterates Overweight on VolitionRX, Maintains $2.5 Price Target
VNRX